Publication not explained
This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.
If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.
Featured Image
Read the Original
This page is a summary of: 2110 POSTER Active specific immunotherapy with NGcGM3/ VSSP/ Montanide ISA-51 (CIMAVaxG) vaccine in the treatment of patients with metastatic breast cancer: Results of a randomized phase II clinical trial, European Journal of Cancer Supplements, September 2007, Elsevier,
DOI: 10.1016/s1359-6349(07)70872-8.
You can read the full text:
Contributors
The following have contributed to this page
